A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

Running, not enrolling · Phase 2

Conditions studied: Duchenne Muscular Dystrophy

In brief

The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory participants with DMD aged ≥ 8 to \< 18 years old receiving corticosteroid therapy.

Key facts

Study ID
NCT06450639
Run by
Hoffmann-La Roche
People needed
30
Starts
2025-04-04
Expected to finish
2026-11-18
Last updated by the study team
2026-05-15

Who can join

Age: 8 and older, up to 17. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.